Focus Partners Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Focus Partners Wealth's REGN Position: Q3 2026 in Review
Focus Partners Wealth increased its Regeneron Pharmaceuticals (REGN) stake by 109% in Q3 2026, buying an estimated $11.6M and bringing the position to 29,358 shares worth $22.3M. The position accounts for 0.02% of the portfolio, ranked #486.
Focus Partners Wealth first reported a position in REGN in Q4 2023 and has held it in 12 quarters since. 1,423 funds tracked by Wall St. Rank hold REGN as of Q3 2026.
- Focus Partners Wealth held 29,358 shares of Regeneron Pharmaceuticals worth $22.3M as of Q3 2026.
- Focus Partners Wealth bought 15,315 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $11.6M.
- Regeneron Pharmaceuticals made up 0.02% of Focus Partners Wealth's portfolio in Q3 2026, its #486 holding.
- Focus Partners Wealth first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
- 1,423 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.
Based on Focus Partners Wealth's 13F filing for Q3 2026, filed 12 Nov 2026.